← All companies

Kyowa Kirin Co., Ltd.

4151 協和キリン株式会社
Semi-annual Report Parent-only Interim (6 months) Pharmaceutical TSE Prime
Revenue
¥263.6bn+14.3% YoY
Net income
¥30.6bn+87.6% YoY
Total assets
¥1.13tn
Compared with
Prior-year interim (6 months)
Fiscal year covered
2026-01-01 – 2026-12-31
EDINET document
S100YTQK
Semi-annual filing. Every figure on this page covers six months, not a full year. It is not annualised.
Not disclosed in this filing: employees, eps, equity_ratio, operating_income, ordinary_income. Shown as a gap rather than estimated.

All reported figures

As filed · extracted from XBRL · no editorial adjustment · hover a row for the XBRL element it came from
ItemJapanesePeriodValue
Revenue売上高Interim (6 months)¥263.6bn
Revenue売上高Prior-year interim (6 months)¥230.7bn
Net income attributable to owners of parent親会社株主に帰属する当期純利益Interim (6 months)¥30.6bn
Net income attributable to owners of parent親会社株主に帰属する当期純利益Prior-year interim (6 months)¥16.3bn
Net cash from operating activities営業活動によるキャッシュ・フローInterim (6 months)¥81.3bn
Net cash from operating activities営業活動によるキャッシュ・フローPrior-year interim (6 months)¥39.8bn
Total assets総資産Interim (6 months)¥1.13tn
Net assets純資産Interim (6 months)¥916.2bn
Net assets純資産Prior-year interim (6 months)¥26.7bn
Cash and cash equivalents現金及び現金同等物Interim (6 months)¥265.1bn
Cash and cash equivalents現金及び現金同等物Prior-year interim (6 months)¥234.6bn
Revenue growth YoY売上高 前年比Interim (6 months)14.3%
Net income growth YoY純利益 前年比Interim (6 months)87.6%
Net margin純利益率Interim (6 months)11.6%
Equity ratio (calculated)自己資本比率(算出)Interim (6 months)81.0%

View the original filing on EDINET →